OTC Artificial Tears Market Report by Product Types, Application, Distribution Channel, Countries and Company Analysis 2026–2034

Global OTC Artificial Tears Market Size and Forecast 2025-2033

Over-the-Counter Artificial Tears Market is projected to grow from US$ 4.32 Billion in 2025 to US$ 6.66 Billion in 2034 at a Compound Annual Growth Rate (CAGR) of 4.92% from 2026 to 2034. The growth of the market is driven by the increasing prevalence of dry eye syndrome, the increasing use of screens, the aging population, and the increasing awareness of eye care. Product development, preservative-free products, and increased availability in retail stores are also driving the market.

OTC Artificial Tears Market Overview

OTC Artificial Tears are over-the-counter lubricating eye drops that help relieve dryness, irritation, burning, and discomfort caused by decreased tear secretion or tear deficiency. They function similarly to tear substitutes by moisturizing the eye surface, adding lubrication, and protecting the eye from environmental factors like dust, wind, pollution, and prolonged computer screen use. They typically contain ingredients such as carboxymethylcellulose, glycerin, or hyaluronic acid that help retain moisture and stabilize the tear film.

OTC Artificial Tears have become extremely popular worldwide because of the rising number of cases of dry eye syndrome, especially among the elderly and digital device users. The rising usage of smartphones, computers, and teleworking has resulted in widespread eye strain and dryness. Additionally, the rising awareness of eye health, easy availability from pharmacies and online shopping platforms, and affordability have all contributed to the rising popularity of OTC Artificial Tears. Preservative-free formulations and advanced lubrication technology have further boosted consumer confidence, making OTC Artificial Tears one of the most widely used eye health products in the world.

Growth Drivers of the OTC Artificial Tears Market

Rising Prevalence of Dry Eye Syndrome and Aging Population

According to a recent study published in the Ocular Surface journal (2024), more than 344 million people worldwide suffered from Dry Eye Disease (DED) in 2024, thus making a significant and increasing disease burden. The increasing number of cases is driving the demand for effective treatment solutions worldwide. Artificial tears are a crucial component in managing symptoms by moisturizing the eyes and relieving irritation, thus driving the market forward. The key driving factor in the growth of the OTC Artificial Tears market is the increasing number of cases of dry eye syndrome worldwide. Dry eye syndrome is a condition in which the eyes either do not produce enough tears or the tears evaporate too quickly, thus causing irritation, redness, and discomfort in the eyes. Aging is a significant contributing factor to dry eye syndrome, as tear production declines with age. The increasing number of the global population aged 60 years and above is driving the demand for artificial tears, as the incidence of chronic eye dryness is rising significantly. In addition, age-related health problems such as diabetes, arthritis, and hormonal imbalances can also contribute to the worsening of symptoms of dry eye. Over-the-Counter Artificial Tears are a readily available, cost-effective, and convenient treatment option for this condition that does not need a prescription. With more awareness about healthcare and people taking proactive measures to stay healthy, patients are taking charge of their eye health. This is especially true among the older demographic, which is driving the demand for Over-the-Counter Artificial Tears.

Increased Screen Time and Digital Eye Strain

According to the Vision Council, 60% of American males and 65% of American females reported symptoms of Computer Vision Syndrome (CVS), highlighting the prevalence of digital eye strain. Approximately 80% of adults use digital devices for at least two hours a day, and more than 65% use two or more devices simultaneously, increasing the possibility of eye strain. Furthermore, almost 80% of adults use digital devices before sleeping, and about 70% reported that their children have access to screens for at least two hours. The simultaneous use of multiple devices has a great impact on the prevalence of CVS, with 75% of multi-device users experiencing CVS compared to 53% of single-device users. The growing dependence on digital technology has resulted in the growing impact of eye irritation, dryness, blurred vision, and irritation. Therefore, the demand for preventive eye care products, such as OTC Artificial Tears, has continued to rise. The growing use of digital devices such as smartphones, laptops, tablets, and televisions has contributed greatly to the growth of the OTC Artificial Tears market. The increased screen time results in a reduction in the rate of blinking, which is very essential for maintaining the tear secretion of the eye. As a result, digital eye strain, dryness, irritation, and fatigue have become common among many people. With the rising trend of teleworking, online learning, gaming, and social media interactions as part of their daily life, dry eye symptoms are becoming common among people of all ages, including the younger generation. Working professionals, students, and businesspeople are most vulnerable due to their prolonged screen time. Over-the-counter Artificial Tears offer immediate relief and help in maintaining eye comfort during prolonged digital screen use. Moreover, rising awareness about digital eye care through health care programs and eye care professionals has encouraged the preventive use of artificial tears. This new trend and growing dependence on digital technology are propelling the market at a fast pace.

Easy Availability and Growth of Retail and E-commerce Channels

The fact that OTC Artificial Tears can be purchased over the counter through different distribution channels has been one of the major factors in the development of the market. The fact that these products can be easily accessed through pharmacies, supermarkets, convenience stores, and online platforms means that consumers can purchase them without having to get medical prescriptions. The development of online shopping has also been an important factor, as it enables consumers to compare products, read reviews, and shop from the comfort of their homes. Online platforms also offer subscription services and discounts, which has been one of the major factors in encouraging repeat business. Pharmaceutical companies have also developed their distribution channels across the globe, ensuring that the product is available in both developed and developing countries. The ease of self-medication and ready relief from symptoms has made OTC Artificial Tears a popular choice for the treatment of mild to moderate dryness of the eyes. In January 2022, Alcon introduced the latest addition to its innovative range of dry eye products in Europe, the Systane Complete Preservative-Free Lubricant Eye Drops, now available in an easy-to-use multi-dose bottle. Systane is the world’s leading Artificial Tears brand.

Challenges of the OTC Artificial Tears Market

Intense Market Competition and Product Differentiation

The OTC Artificial Tears market is highly competitive, with many global and local players competing with similar products. Most of the artificial tear products in the market have similar active ingredients, providing similar therapeutic benefits, making it highly difficult for players to differentiate their products. This high level of competition often leads to pricing pressure, resulting in lower profit margins for players. In addition, the presence of generic and low-cost alternatives makes consumers highly sensitive to prices, especially in developing countries. Players in this market have to heavily invest in R&D to develop innovative products, such as preservative-free drops or long-lasting artificial tears, to differentiate themselves in the market. Marketing and branding efforts also require heavy investments to win consumer trust and recognition. Small players may find it difficult to compete with highly established brands, which enjoy strong distribution networks and consumer loyalty. This highly fragmented and competitive market is a major challenge to growth and profitability in the OTC Artificial Tears market.

Risk of Product Recalls and Safety Concerns

Product safety and quality concerns are one of the biggest challenges in the OTC Artificial Tears market. Artificial tears are highly sensitive products that come into direct contact with the eyes. Therefore, they need to be strictly safe and sterile. If any contamination occurs during the manufacturing or packaging process, it can lead to serious eye infections, irritation, or reactions. Product recalls due to contamination or quality concerns can lead to damage to the brand, loss of consumer confidence, and financial losses for the manufacturer. The regulatory authorities strictly monitor ophthalmic products and need strict adherence to quality guidelines and manufacturing processes. Following these regulatory requirements can lead to an increase in production complexity and costs. Additionally, negative publicity or consumer concerns about product safety can lead to a loss of market confidence. The manufacturers need to invest in advanced production technology and quality to ensure product safety and consumer confidence in the OTC Artificial Tears market.

Ointment OTC Artificial Tears Market

Ointment OTC Artificial Tears is a niche market for artificial tears, which is designed specifically to provide thicker and longer-lasting tear lubrication compared to the liquid form of eye drops. These ointments contain thicker ingredients such as mineral oil or petrolatum, which work to create a protective barrier on the surface of the eye and prevent the evaporation of tears. They are especially useful for patients with severe dry eye syndrome, irritation, and night dryness. Patients typically apply these ointments before bedtime because of their thick viscosity, which causes temporary blurred vision but provides long-lasting tear hydration during the night. The increasing awareness of advanced dry eye treatments and the rising number of patients with severe dryness due to aging, digital device usage, and environmental factors are driving the demand. Healthcare professionals typically prescribe ointments for long-term relief when patients experience inadequate relief from standard eye drops. As patients seek more effective and longer-lasting treatments, the ointment market is gradually increasing in the OTC Artificial Tears market.

Dry Eye Syndrome Market     

The market for Dry Eye Syndrome is growing at a rapid rate due to the rising number of people experiencing dryness, irritation, and inflammation in the eyes. This is because the eyes are not able to produce enough tears or the quality of the tears is poor. This results in irritation and vision problems. Aging, the use of computers, pollution, and some diseases have all added to the rising number of people experiencing this problem. Office-going individuals, computer users, and older people are the most prone to this problem. Rising awareness about eye health has resulted in more people seeking treatment for this problem. This includes over-the-counter artificial tears and prescription drugs. Preventive measures and regular eye check-ups are being advocated by healthcare professionals. This is also adding to the growth of the Dry Eye Syndrome market. Effective treatment formulations have made it easier for people to deal with the symptoms of this problem.

UV and Blue Light Protection Market

The UV and Blue Light Protection market is witnessing growth as a result of the rising exposure to harmful light sources from both natural sunlight and digital devices. Ultraviolet (UV) light from the sun and blue light from smartphones, computers, and LED screens can lead to eye strain, dryness, and possible long-term vision problems. As people continue to spend more time outdoors and on digital devices, there has been a substantial rise in awareness regarding the possible dangers posed by exposure to light. This, in turn, has led to an increase in the demand for protective eye care products such as lubricating eye drops, protective eyewear, and specialized artificial tears. These products help to alleviate eye strain, offer comfort, and protect the eye surface. The rising digital lifestyle trends and awareness regarding the environment are also adding to the growth of the UV and Blue Light Protection market.

OTC Artificial Tears Retail Pharmacies Market

Retail pharmacies are one of the most important distribution channels for Over-the-Counter Artificial Tears, as they provide easy and immediate access to the product. Retail pharmacies are considered trustworthy healthcare destinations where customers can get access to a range of eye care products, including various types of artificial tears for various levels of dryness and irritation. Retail pharmacists also prove to be important influencers in suggesting suitable products based on individual needs, which helps in creating consumer confidence and hence increasing sales. The wide reach of retail pharmacy chains in both urban and rural areas ensures that the products are accessible to a larger population. In addition, the rising trend of self-medication and quick relief from symptoms also helps in increasing sales in retail pharmacies. Retail pharmacies also provide competitive pricing for private-label artificial tears.

United States OTC Artificial Tears Market

The United States OTC Artificial Tears market is one of the largest in the world because of the high incidence of dry eye syndrome and awareness among consumers about eye health. Digital device use, aging populations, and exposure to air conditioning and environmental pollutants are some of the factors that have resulted in the high incidence of eye dryness and irritation. Consumers are actively searching for OTC products to provide immediate relief, which has resulted in a high demand for products. The presence of large pharmaceutical companies, advanced healthcare infrastructure, and innovation in products has further strengthened the market. Preservative-free products and premium lubricating eye drops are also in high demand among sensitive consumers. In June 2023, Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) had approved VEVYE™ (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease. Most recently, in February 2025, Alcon, a global leader in eye care, introduced SYSTANE PRO Preservative-Free (PF) in the United States. This over-the-counter eye drop has a triple-action, preservative-free formula and is the longest-lasting product in the SYSTANE line, providing relief from burning, dryness, and irritation for an extended period of time.

United Kingdom OTC Artificial Tears Market

The United Kingdom OTC Artificial Tears market is growing steadily due to increased screen time, the aging population, and increased awareness of eye health. A large number of people in the UK are using computers and digital devices on a daily basis for work, educational, and entertainment purposes, which results in digital eye strain and dry eye conditions. In addition, the rising number of older people makes them more susceptible to the decrease in tear production, thereby creating a demand for tear-forming eye products. Consumers in the UK are increasingly adopting the use of OTC Artificial Tears as a convenient and cost-effective solution. The increased accessibility of products via pharmacies, optometrists, and online shopping platforms has made it easier for people to access the products. Healthcare professionals such as optometrists and pharmacists often prescribe artificial tears to patients for the treatment of mild to moderate dry eye conditions. The developed healthcare infrastructure and the rising interest in preventive eye care practices continue to drive the market in the United Kingdom. June 2025, Nordic group BV, the worldwide pharmaceutical company operating under the name Nordic Pharma, announced that the dry eye treatment, Lacrifill canalicular gel, has received CE mark approval for distribution in Europe.

India OTC Artificial Tears Market

The OTC Artificial Tears market in India is growing at a fast pace owing to the increasing use of digital devices, urbanization, and increasing awareness among people regarding eye health. As more people are getting exposed to technology-based work environments and spending more time on smartphones and computers, the cases of eye strain and dryness have increased significantly. Environmental factors such as dust, pollution, and extreme temperatures also contribute to eye irritation. The growing middle-class population and easy availability of healthcare products have encouraged consumers to choose OTC healthcare products. The retail pharmacy and online platforms are increasing in urban and semi-urban areas, making artificial tears more accessible. In addition, health awareness campaigns and eye care initiatives are promoting the treatment of dry eye symptoms at the early stage. April 2023 - Sun Pharmaceutical Industries Limited has announced that one of its wholly owned subsidiaries has launched a new product in the ophthalmology division, CEQUA®, in India for patients suffering from Dry Eye Disease (DED) with inflammation, which is a very common condition. CEQUA® is the first dry eye treatment launched in India, which is delivered through nanomicellar (NCELL®) technology.

Saudi Arabia OTC Artificial Tears Market

The Saudi Arabian OTC Artificial Tears market is growing steadily due to the harsh environmental conditions and increasing awareness regarding eye care. The Saudi Arabian climate is extremely hot and arid, and the constant exposure to dust and air conditioning further exacerbates the irritation in the eyes of the people. Furthermore, the increasing use of digital gadgets for both personal and professional reasons has further resulted in the increased incidence of dry eye syndrome. People are now increasingly turning to the use of OTC Artificial Tears. The development of retail pharmacy chains and advancements in the healthcare infrastructure have further enhanced the availability of the product in the urban regions. Healthcare professionals are also creating awareness regarding the preventive care of the eyes and advising the early use of lubricating eye drops. Furthermore, the increasing disposable incomes and increasing awareness regarding health among the consumers have further fueled the use of premium eye care products, thus contributing to the steady growth of the OTC Artificial Tears market in Saudi Arabia. Jan. 2026, LENZ Therapeutics, Inc., and Lunatus Marketing & Consulting FZCO signed an exclusive distribution agreement for Lunatus to register and distribute VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Lunatus is an independent pharmaceutical company focused on the commercialization of pharmaceutical products in the Middle East.

Market Segmentation

Product Type

• Solution
• Ointment
• Emulsion
• Gel
• Spray Solution
• Suspensions

Application

• Dry Eye Syndrome
• Allergies
• Infections
• UV and Blue Light Protection
• Contact Lens Moisture Retention
• Others

Distribution Channel

• Drugstores & Supermarkets
• Online Pharmacies
• Retail Pharmacies
• Others

Countries- Industry is divided into 25 viewpoints:

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil     
• Mexico  
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All the Key players have been covered

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Competitive Landscape

• AbbVie Inc.
• Akorn Inc.
• Alcon
• Bausch Health Companies Inc.
• Johnson & Johnson
• Nicox S.A.
• Novartis AG
• Santen Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Ltd.

Report Details: